Full-Time

Operational Excellence Manager

Production

Zeiss

Zeiss

1,001-5,000 employees

Corporate venture capital for deep-tech startups

Compensation Overview

$101k - $125k/yr

+ Performance bonus

Company Does Not Provide H1B Sponsorship

Maple Grove, MN, USA

In Person

On-site five days per week; occasional domestic and international travel required.

Bachelor's, Associate's

Category
Manufacturing & Production Operations
Required Skills
ERP
Six Sigma
SAP Products
PLC
OSHA
Oracle

Get referred to Zeiss

See people who can refer or advise you

Requirements
  • A bachelor's degree in industrial, mechanical, manufacturing engineering, or a related field; a two-year technical degree is acceptable with strong relevant experience.
  • At least 7 years of progressive experience in high-volume, lean manufacturing, including at least 2 years in a people leadership or management role.
  • Deep knowledge of Lean methodologies and Value Stream Mapping with proven implementation success.
  • A solid understanding of manufacturing methods, assembly processes, and standard work.
  • The ability to read and interpret engineering drawings and blueprints.
  • Working knowledge of enterprise resource planning systems for production and inventory control; SAP is preferred, while Oracle or similar systems are acceptable.
  • The ability to interpret programmable logic controller-driven data and key production performance indicators for decision-making.
  • Strong leadership, sound decision-making, and the ability to grow and develop a high-performing team.
  • A proven track record of managing and driving measurable performance improvement.
  • Strong shop-floor credibility and the ability to communicate effectively at all levels, from operators to senior leadership, both orally and in writing.
Responsibilities
  • Provide hands-on Gemba leadership, spending 60–70% of time on the shop floor to identify bottlenecks, safety hazards, and waste and support teams in meeting daily, weekly, and monthly production goals.
  • Plan, develop, and motivate a high-performing team; hire, coach, and manage performance in line with company policies and core values.
  • Ensure line leads perform their duties to build and develop teams, and ensure roles and responsibilities between operators and line leads are fulfilled.
  • Implement and sustain Daily Management Systems, including visual boards, tiered accountability meetings, Lean techniques, and 6S standards.
  • Lead rapid problem-solving through root cause analysis and Kaizen events, ensuring timely resolution of production issues and quality defects.
  • Analyze production key performance indicators to reduce downtime, improve takt times and machine build times, and drive continuous improvements in throughput, quality, and cost.
  • Develop hands-on training on Standard Work and maintain a training matrix for all shop-floor employees.
  • Ensure routing and build procedures are current and compliant with ISO and internal product requirements, and coordinate timely implementation of engineering changes.
  • Ensure all production equipment is properly maintained, calibrated, and in good working order.
  • Maintain a clean, safe, and ergonomic work environment; complete safety reports and provide training in accordance with OSHA and company standards.
  • Lead escalations through the organization in a timely manner.
  • Model behaviors aligned with company values and perform other related duties as required.
Desired Qualifications
  • Six Sigma Green Belt or Black Belt certification.

ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$67.7M

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ZEISS Ventures led SeeTrue's €2.2 million round on 2026-08-05, reinforcing eye-tracking leadership.
  • ZEISS backed Maculaser and Custom Surgical in 2026, deepening ophthalmology innovation pipelines.
  • ZEISS launched Otus ML 1.4/35, Panoptes 65, and DuraVision Plus in 2026.

What critics are saying

  • ZEISS Meditec plans up to 1,000 job cuts through 2028/29 after 5.7% revenue decline.
  • ProfitUp requires over €150m restructuring costs, signaling weak margins and execution strain.
  • If ophthalmology turnaround fails, ZEISS Meditec drags group cash flow and venture appetite.

What makes Zeiss unique

  • ZEISS Ventures backs deep-tech tied to ZEISS optics, medtech, and industrial workflows.
  • ZEISS brings distribution, engineering, and clinical validation to early startups like Custom Surgical.
  • ZEISS spans lenses, microscopy, and eye care, creating cross-selling across adjacent markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Company News

Yahoo Finance
Aug 27th, 2026
ZEISS launches DORC EVA NEXUS cataract system at ESCRS in London

ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.

ZEISS
Aug 5th, 2026
ZEISS leads $2.5M investment in SeeTrue Technologies for miniaturised eye-tracking tech

ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.

PR Newswire
Jun 11th, 2026
ZEISS completes early implantations of AT LUCIA toric 721P intraocular lens

ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.

ZEISS
May 28th, 2026
ZEISS invests in Maculaser to advance temperature-controlled retinal laser therapy

ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.